Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Skeletal muscle mass" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Skeletal Muscle Mass: (also known as SMM) Amount of muscle attached to the bones (muscle most easily affected through exercise) Body Fat Mass: Sum of subcutaneous fat, visceral fat, and fat surrounding the muscles.
Antisense composition and method for treating muscle atrophy
Owner:AVI BIOPHARMA
Antisense composition and method for treating muscle atrophy
A method and compound for treating skeletal muscle mass deficiency in a human subject are disclosed. The composition is an oligomer of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, contains between 10-40 nucleotide bases, has a base sequence effective to hybridize to an expression-sensitive region of processed or preprocessed human myostatin RNA transcript, identified, in its processed form, by SEQ ID NO:6, and is capable of uptake by target muscle cells in the subject. In practicing the method, the compound is administered in an amount and at a dosage schedule to produce an overall reduction in the level of serum myostatin measured in the patient, and preferably to bring the myostatin level within the a range determined for normal, healthy individuals.
Owner:AVI BIOPHARMA
Use of arachidonic acid as a method of increasing skeletal muscle mass
InactiveUS6841573B2Increase skeletal muscle massFast metabolismBiocideAnimal repellantsSerum igeSkeletal muscle mass
This invention discloses a method of orally administering arachidonic acid for the purpose of increasing the serum level of the prostaglandin PGF2alpha and subsequently the level of retained skeletal muscle mass.
Owner:MN INTELLECUTUAL PROPERTY
Methods for determining total body skeletal muscle mass
InactiveUS20140353486A1Facilitate wide-spread adaptationComponent separationVaccination/ovulation diagnosticsDiseaseBacteriuria
The present invention is based on the finding that enrichment of D3-creatinine in a urine sample following oral administration of a single defined dose of D3-creatine can be used to calculate total-body creatine pool size and total body skeletal muscle mass in a subject. The invention further encompasses methods for detecting creatinine and D3-creatinine in a single sample. The methods of the invention find use, inter alia, in diagnosing disorders related to skeletal muscle mass, and in screening potential therapeutic agents to determine their effects on muscle mass.
Owner:RGT UNIV OF CALIFORNIA +1
Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof
InactiveUS20100173829A1Effect body weightEffect responsivenessAntibacterial agentsOrganic active ingredientsAcute hyperglycaemiaLipid formation
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity. Also provided are pharmaceutical compositions for use thereof.
Owner:ASTON UNIV
Methods for identifying compounds for regulating muscle mass or function using dopamine receptors
Owner:PROCTER & GAMBLE CO
Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
InactiveUS20060198842A1Compounds screening/testingPeptide/protein ingredientsCorticotropinsScreening method
Owner:APTALIS PHARMA
Transgenic Mouse Models for Diseases Caused by mtDNA Mutations and Related Methods
InactiveUS20100169985A1Improve developmentImprove satisfactionCompounds screening/testingDermatological disorderCochlear degenerationHeart disease
Animal models and methods wherein homoplasmic and heteroplasmic mtDNA mutation(s) are induced in an animal (e.g., a mouse) to cause or facilitate the development of a disorder (e.g., disease, malformation, defect, abnormality or other disorder). In at least some embodiments, the mtDNA mutation(s) will cause or facilitate the development of an age-related disorder, such as a cardiac disease, cardiomyopathy, muscle disease, cancer, abnormaly in tissues of high cellular turnover, heart dysfunction, graying of hair, alopecia, auditory function loss, cochlear degeneration, immune cell loss, anemia, male germ cell loss leading to lack of sperm and infertility, skeletal muscle mass loss (sarcopenia), neurodegeneration, increased presence of apoptotic markers, and loss of bone mass.
Owner:RGT UNIV OF CALIFORNIA
Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.
Owner:APTALIS PHARMA
Methods for identifying compounds for regulating muscle mass or function using dopamine receptors
Screening methods for identifying compounds that bind to or activate (D1 or D5 dopamine receptors individually or in combination) or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of D1 or D5 dopamine receptors or of D1 or D5 dopamine receptor signal transduction pathways and increase D1 or D5 dopamine receptor expression. Pharmaceutical compositions comprising D1 or D5 dopamine receptor agonists, antibodies to D1 or D5 dopamine receptors and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using D1 or D5 dopamine receptors as the target for intervention and methods for treatment of muscular dystrophies are described.
Owner:THE PROCTER & GAMBLE COMPANY
Therapeutic vaccine for Myostatin specific antibody and its preparation method
InactiveCN101057970AImproving immunogenicityQuality improvementGenetic material ingredientsMuscular disorderEscherichia coliBALB/c
The invention discloses a curative vaccine for Myostatin specific antibody and the method for preparing the same. The human myostatin C-end gene section that is connected with Th cell auxiliary epitope TT830-844 at N-end is prepared by using artificial DNA synthesizing method. The genetic sequence is TT-Ms, and the TT-Ms genetic section is cloned to pQE30 pronucleus expression carrier to construct pQE-TT-Ms recombinant expression carrier, and constructs pQE-Ms recombinant expression carrier by PCR augmenting Ms genetic section. The fused protein His-TT-Ms and His-Ms is expressed in bacillus coli, and is used as protein vaccine for myostatin after certification. The synthesized TT-Ms genetic section is cloned to specific plasmid of pVAC1-cms gene vaccine, and constructs pVAC-TT-Ms recombinant plasmid, and it is used as myostatin gene vaccine after external certification for target protein expression. The constructed Myostatin protein vaccine and gene vaccine is used in healthy adult BALB / c mouse, the specific antibody of myostatin molecule for human can be induced, and the quality and force of skeletal muscles of mouse is obviously improved.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Pharmaceutical composition for treating sarcopenia including glucagon-like peptide-1 receptor agonist
ActiveUS20180153964A1Lose weightPeptide/protein ingredientsGenetic material ingredientsGlucagon-like peptide-1Secretion
Provided are a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia provided in the present invention is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states, and therefore, the composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.
Owner:IMMUNOFORGE CO LTD
Methods for identifying compounds for regulating muscle mass or function using dopamine receptors
Screening methods for identifying compounds that bind to or activate (D1 or D5 dopamine receptors individually or in combination) or regulate or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of D1 or D5 dopamine receptors or of D1 or D5 dopamine receptor signal transduction pathways and increase D1 or D5 dopamine receptor expression. Pharmaceutical compositions comprising D1 or D5 dopamine receptor agonists, antibodies to D1 or D5 dopamine receptors and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using D1 or D5 dopamine receptors as the target for intervention and methods for treatment of muscular dystrophies are described.
Owner:THE PROCTER & GAMBLE COMPANY
Preservation of bodily protein
InactiveUS20020147237A1Avoid exerting an extra metabolic strain on the patientEfficient removalBiocideMetabolism disorderSkeletal muscle massGreek letter alpha
A method of preserving bodily protein stores such as skeletal muscle mass in a catabolic patient involves the concomitant administration (a) alpha-KG and / or alpha-KGA and (b) ammonium in amounts effective to preserving skeletal muscle. Also disclosed is the combination of a first pharmaceutical composition comprising alpha-KG and / or alpha-KGA in a pharmaceutically acceptable carrier and a second pharmaceutical composition comprising ammonium in a pharmaceutically acceptable carrier, in amounts effective to preserving skeletal muscle.
Owner:PHARMALINK
Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.
Owner:APTALIS PHARMA
Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
ActiveUS10993993B2Lose weightPeptide/protein ingredientsAntibody mimetics/scaffoldsPharmaceutical drugAgonist
A pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states. The composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.
Owner:IMMUNOFORGE CO LTD
Therapeutic vaccine for Myostatin specific antibody and its preparation method
InactiveCN100586476CImproving immunogenicityQuality improvementGenetic material ingredientsMuscular disorderEscherichia coliBALB/c
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
InactiveUS20140243259A1Antibacterial agentsOrganic active ingredientsAcute hyperglycaemiaBlood plasma
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity. Also provided are pharmaceutical compositions for use thereof.
Owner:ASTON UNIV
Use of indirubin as a dietary supplement
InactiveUS20070161694A1Increase skeletal muscle massReduce the total massBiocideAnimal repellantsDietary supplementSkeletal muscle mass
A method is disclosed for administering naturally occurring chemical Indirubin or its derivatives such as, for example, Indirubin-3′-monoxime, as a method of increasing skeletal muscle mass, decreasing skeletal muscle breakdown and / or decreasing fat mass.
Owner:WELLNESS
Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
InactiveUS20160220635A1Antibacterial agentsOrganic active ingredientsAcute hyperglycaemiaBlood plasma
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity. Also provided are pharmaceutical compositions for use thereof.
Owner:ASTON UNIV
Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (glp-1) or glp-1 receptor agonist
ActiveUS20190046614A1Lose weightPeptide/protein ingredientsAntibody mimetics/scaffoldsAgonistSecretion
A pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states. The composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.
Owner:IMMUNOFORGE CO LTD
Methods for identifying compounds for regulating muscle mass or function using prostanoid IP receptors
Methods for identifying compounds that bind to or activate prostanoid IP receptors and potentially regulate skeletal muscle mass or function are disclosed. Pharmaceutical compositions comprising IP receptor agonists and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using IP receptor as the target for intervention and methods for treatment of muscular dystrophies are described.
Owner:THE PROCTER & GAMBLE COMPANY
Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to novel uses of muscle-derived progenitor cells for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass.
Owner:UNIVERSITY OF PITTSBURGH +1
Methods for determining total body skeletal muscle mass
ActiveUS20160220182A1Facilitate wide-spread adaptationComponent separationSurgeryDiseaseSingle sample
Owner:RGT UNIV OF CALIFORNIA +1
Pharmaceutical composition for treating sarcopenia including glucagon-like peptide-1 receptor agonist
ActiveUS10751392B2Lose weightPeptide/protein ingredientsGenetic material ingredientsPharmaceutical drugAgonist
Provided are a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia provided in the present invention is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states, and therefore, the composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.
Owner:IMMUNOFORGE CO LTD
Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to novel uses of muscle-derived progenitor cells for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass.
Owner:UNIVERSITY OF PITTSBURGH +1
Use of a sclerostin antagonist
PendingUS20210198350A1Dose be reduced and increasedEasy to manageSkeletal disorderImmunoglobulins against growth factorsMyopathyAntiendomysial antibodies
The present invention relates to methods and compositions for treating a myopathy in a subject, comprising administering a therapeutically effective amount of a sclerostin antagonist to the subject. The myopathy may be characterized by a loss of skeletal muscle mass, size, strength and / or function. The sclerostin antagonist may be an anti-sclerostin antibody.
Owner:MEREO BIOPHARMA 3 LTD
Sarcopenia data acquisition system based on household body composition instrument and intelligent equipment
PendingCN112656396AEase of evaluationDiagnostic recording/measuringSensorsHuman bodyBody composition measure
The invention discloses a sarcopenia data acquisition system based on a household body composition instrument and intelligent equipment. The sarcopenia data acquisition system comprises a body composition measuring module, a grip strength measuring module, a step speed measuring module, a cloud data processing and storage module and an intelligent terminal display module. The human body composition measuring module measures human limb skeletal muscle mass indexes through a bioelectrical impedance method, the grip strength measuring module uses a pressure sensor to measure grip strength, and the step speed measuring module measures the 6-meter walking speed of a user through a smart phone or a wristband. The cloud data processing and storing module receives and processes the data transmitted by the measuring module to evaluate the sarcopenia disease risk of the user and store the data, and the intelligent terminal displays the user measuring result and the sarcopenia disease risk evaluation result. The human limb skeletal muscle quality index, grip strength and 6-meter step speed can be obtained, the risk of suffering from sarcopenia of the user is evaluated according to the obtained parameters, and help can be provided for the user to autonomously evaluate the risk of suffering from sarcopenia.
Owner:HEFEI INSTITUTES OF PHYSICAL SCIENCE - CHINESE ACAD OF SCI
Use of arachidonic acid as a method of increasing skeletal muscle mass
InactiveUS20050137256A1Increase skeletal muscle massFast metabolismBiocideMuscular disorderArachidonic acid supplementationSkeletal muscle mass
This invention discloses a method of orally administering arachidonic acid and its derivatives for the purpose of increasing the serum level of the prostaglandin PGF2alpha and subsequently the level of retained skeletal muscle mass.
Owner:LLEWELLYN WILLIAM C
Transgenic mouse models for diseases caused by mtDNA mutations and related methods
InactiveUS8203030B2Improve satisfactionMassive lossCompounds screening/testingDermatological disorderAge related diseaseCochlear degeneration
Animal models and methods wherein homoplasmic and heteroplasmic mtDNA mutation(s) are induced in an animal (e.g., a mouse) to cause or facilitate the development of a disorder (e.g., disease, malformation, defect, abnormality or other disorder). In at least some embodiments, the mtDNA mutation(s) will cause or facilitate the development of an age-related disorder, such as a cardiac disease, cardiomyopathy, muscle disease, cancer, abnormaly in tissues of high cellular turnover, heart dysfunction, graying of hair, alopecia, auditory function loss, cochlear degeneration, immune cell loss, anemia, male germ cell loss leading to lack of sperm and infertility, skeletal muscle mass loss (sarcopenia), neurodegeneration, increased presence of apoptotic markers, and loss of bone mass.
Owner:RGT UNIV OF CALIFORNIA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com